← All trials
NCT05683600
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 29, 2022
- Primary completion
- Jul 12, 2023
- Completion date
- Jul 12, 2023
- First posted
- Jan 13, 2023
- Last posted
- Sep 28, 2023
- Enrollment
- 3000
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Government of ChinaLead sponsor
- Government of ChinaOverall official - principal investigator
- Government of ChinaCollaborator
- Government of ChinaOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.